Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Trial Profile

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms MIP
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Aug 2016 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
    • 26 Jan 2016 Changed planned patient number and treatment arms , as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top